• FDA Approves Pembrolizumab for TMB-H Solid Tumors americanpharmaceuticalreview
    June 28, 2020
    The Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) ...
PharmaSources Customer Service